Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.45 |
| ▸ | EIF4A1 | P60842 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4480191 | 0.86 | LMNA (0.55) | LMNAHTTSMN1; SMN2TSHRALOX15 | |
| SCHEMBL4477612 | 0.84 | LMNA (0.52) | LMNAHTTSMN1; SMN2TSHRALOX15 | |
| SCHEMBL4487201 | 0.84 | LMNA (0.52) | LMNAHTTSMN1; SMN2TSHRALOX15 | |
| SCHEMBL4479739 | 0.83 | LMNA (0.58) | LMNAHTTSMN1; SMN2TSHRALOX15 | |
| SCHEMBL4468509 | 0.83 | LMNA (0.51) | LMNAHTTSMN1; SMN2TSHRALOX15 | |
| SCHEMBL4491823 | 0.83 | LMNA (0.51) | LMNAHTTSMN1; SMN2TSHRALOX15 | |
| SCHEMBL10560738 | 0.82 | MEN1 (0.56) | SMN1; SMN2DAGLAEIF4A1 | |
| SCHEMBL4475623 | 0.82 | LMNA (0.55) | LMNAHTTSMN1; SMN2TSHRALOX15 | |
| SCHEMBL4471470 | 0.81 | LMNA (0.55) | LMNAHTTSMN1; SMN2TSHRALOX15 | |
| SCHEMBL4485637 | 0.78 | PRMT1 (0.50) | LMNAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534804-B2 | Benzoxazole inhibitors of 15-lipoxygenase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-19 | — | — | US | claimed |
| US-20070049628-A1 | Benzoxazole inhibitors of 15-lipoxygenase | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-01 | — | — | US | claimed |
| US-7534804-B2 | Benzoxazole inhibitors of 15-lipoxygenase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-19 | — | — | US | disclosed |
| US-7534804-B2 | Benzoxazole inhibitors of 15-lipoxygenase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-19 | — | — | US | disclosed |
| US-7534804-B2 | Benzoxazole inhibitors of 15-lipoxygenase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-19 | — | — | US | disclosed |
| US-20070049628-A1 | Benzoxazole inhibitors of 15-lipoxygenase | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-01 | — | — | US | disclosed |
| US-20070049628-A1 | Benzoxazole inhibitors of 15-lipoxygenase | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-01 | — | — | US | disclosed |
| US-20070049628-A1 | Benzoxazole inhibitors of 15-lipoxygenase | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049628-A1 | Benzoxazole inhibitors of 15-lipoxygenase | ALOX15, ALOX5, ALOX15B | LMNA 579/4885HTT 3784/4885SMN1; SMN2 4619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.